Efficacy of solifenacin for overactive bladder symptoms, symptom bother, and health-related quality of life in patients by duration of self-reported symptoms: a secondary analysis of the VIBRANT study.
In this post-hoc analysis of data from patients with overactive bladder (OAB) in VIBRANT patients receiving solifenacin showed statistically significantly greater improvement versus placebo in most outcome measures regardless of OAB symptom duration (less than five years and five years or longer).
Metropolitan Urology, Jeffersonville, IN, USA.
SourceUrologic nursing 32:1 pg 38-46, 50
Quality of Life
Randomized Controlled Trials as Topic
Urinary Bladder, Overactive
Pub Type(s)Journal Article
Research Support, Non-U.S. Gov't